Roles of neutrophil/lymphocyte ratio in prognosis and in differentiation of potential beneficiaries in HER2-positive breast cancer with trastuzumab therapy

Table 2 Treatment for 843 HER2-positive BC patients

Treatment	Without trastuzumab	With trastuzumab		p-value
Treatment	Group 1 n(%)	Group 2 n(%)	Group 3 n(%)	p-value
Chemotherapy regimen
EC-T	203 (79.6)	248 (84.4)	238 (81.0)	0.846
TCb	37 (14.5)	35 (11.9)	39 (13.3)
P	8 (3.1)	6 (2.0)	10 (3.4)
Others	7 (2.7)	5 (1.7)	7 (2.9)
Radiotherapy
No	114 (44.7)	124 (42.2)	141 (48.0)	0.369
Yes	141 (55.3)	170 (57.8)	153 (52.0)
Endotherapy
No	142 (55.7)	162 (55.1)	160 (54.4)	0.956
Yes	113 (44.3)	132 (44.9)	134 (45.6)
Total	255 (100.0)	294 (100.0)	294 (100.0)

Group 1 contained patients without trastuzuamb treatment, group 2 contained patients with trastuzuamb and low pre-NLR value, and group 3 contained patients with trastuzuamb and high pre-NLR value. EC-T, epirubicin and cyclophosphamide followed by the taxane; TCb, docetaxel and carboplatin; P, taxane; NLR, neutrophil/lymphocyte ratio

ISSN: 1471-2407